Pozen (POZN): Another Microcap Biotech Falls Apart

Print Email

Pozen (POZN) got the bad news that the FDA has "delayed approval of an experimental two-in-one migraine drug from GlaxoSmithKline (GSK)", according to Reuters.  The drug, Trexima combines Glaxo’s popular migraine drug Imitrex with the older painkiller naproxen sodium.

Pozen’s shares dropped 45% to $9.55. Its market cap is now $285 million, but over the last year, it has been as high as $500 million.

It is a frightening valuation for a company that is virtually a one-trick pony. In the last reported quarter, Pozen has revenue of $7.7 million and an operating loss of $2.9 million.

Even with the drop, the stock still seems high.

Douglas A. McIntyre